Quick Answer
Emergent BioSolutions Inc. reported Cash And Cash Equivalents At Carrying Value of $99.50 million for the year ending 2024.
- Emergent BioSolutions Inc. showed a decrease of -10.9% in Cash And Cash Equivalents At Carrying Value from 2023 to 2024.
- This data is from Emergent BioSolutions Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2025.
- XBRL data for this metric is available from 2008 to 2024 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2008 to 2024), Emergent BioSolutions Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 8.8%.
- Historical annual values: Fiscal year 2024: $99.50 million | Fiscal year 2023: $111.70 million | Fiscal year 2022: $642.60 million | Fiscal year 2021: $576.10 million | Fiscal year 2020: $621.30 million | Fiscal year 2019: $167.80 million | Fiscal year 2018: $112.20 million | Fiscal year 2017: $178.30 million | Fiscal year 2016: $271.50 million | Fiscal year 2015: $312.80 million | Fiscal year 2014: $280.50 million | Fiscal year 2013: $179.34 million | Fiscal year 2012: $141.67 million | Fiscal year 2011: $143.90 million | Fiscal year 2010: $169.02 million | Fiscal year 2009: $102.92 million | Fiscal year 2008: $91.47 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: